6Agrawal S, Bonlovsky HL. Management of nonalcoholic steatohepatits: an analvtic review. I Clin Gastroenterol. 2002.35:253-261.
7Yanovski SZ, Yanovski JA. Obesity. N Engl J Med, 2002,346:591-602.
8Inzucchi SE. Oral antihyperglycemic therapy for type Ⅱ diabetes. JAMA, 2002,287 : 360-372.
9Li Z, Yang S, Lin H, et al. Probioties and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease.Hepatology . 2003.37:343-350.
10Svegliati-Baroni G, Saccomanno S, Vangoor H, et al. Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells. Liver, 2001,12 : 1-12.
1Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Ann Rev Biochem, 2003, 72:137-174.
2Paumgartner G, Beuers U. Mechanisms of action and therapeutic efficacy of ursodeoxycholic acid in cholestatic liver disease. Clin Liver Dis,2004, 8:67-81.
3Lutjohann D, Hahn C, Prange W, et al. Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men. Int J Clin Pharmacol Ther, 2004,42: 307-313.
4Kullak-Ublick GA, Stieger B, Meier PJ. Enterohepatic bile salt transporters innormal physiology and liver disease. Gastroenterology,2004, 126:322-342.
5Vilca Melendez H, Rela M, Setchell KD, et al. Bile acids analysis: a tool to assess graft function in human liver transplantation. Transpl Int, 2004, 17:286-292.
6Bore KE, Heubi JE, Balistreri WF, et al. Bile Acid synthetic defects and liver disease: a comprehensive review. Pediatr Der Pathol, 2004,7:315-334.
7Anwer MS. Cellular regulation of hepatic bile acid transport in health and cholestasis. Hepatology, 2004, 39:581-190.
